Published January 1, 2025
| Version v1
Journal article
Open
Carcinoma hepatocelular y trasplante hepático
Authors/Creators
- 1. Hospital Universitari i Politècnic La Fe. IISLaFe, Departamento de Medicina, Universidad de Valencia, CIBER de Enfermedades hepáticas y digestivas (Ciberehd), València, Spain
Description
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide and constitutes a major indication for liver transplantation (LT). This article provides a comprehensive review of the current epidemiology of LT for HCC, analyzing global trends. Accepted and expanded indications for LT are detailed, including key selection models such as Milan, UCSF, Up-to-Seven, Metroticket 2.0, and NYCA criteria. Bridging therapies and downstaging strategies are thoroughly discussed, highlighting the integration of locoregional therapies and immunotherapy in the pre-transplant setting. Post-transplant recurrence prediction models are critically analyzed, with an emphasis on the emerging role of circulating tumor DNA (ctDNA). Finally, a risk-stratified surveillance protocol is proposed, emphasizing the need for a personalized approach in post-transplant follow-up. Copyright © 2025 ARÁN EDICIONES, S. L.